Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer

• मुख्य लेखकों: Vergnenègre A (लेखक), Ray JA (लेखक), Chouaid C (लेखक), Grossi F (लेखक), Bischoff HG (लेखक), Heigener DF (लेखक), Walzer S (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: Dove Medical Press, 2012-01-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Alain Vergnenègre1, Joshua A Ray2, Christos Chouaid3, Francesco Grossi4, Helge G Bischoff5, David F Heigener6, Stefan Walzer21Department of Pneumology, Hôpital du Cluzeau, Limoges, France; 2Global Health Economics and Strategic Pricing, F Hoffmann-La Roche Ltd, Basel, Switzerlan...